FLNA FILANA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1069530 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY60.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-60.5%
ROA-36.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets42.1%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $26.59M | $69.64M |
| SG&A expense | $68.80M | $71.81M |
| Operating income | -$95.39M | -$141.45M |
| Income tax | $0 | $0 |
| Net income | -$90.97M | -$24.34M |
| EBITDA | -$94.49M | -$140.49M |
| EPS (basic) | -1.88 | -0.53 |
| EPS (diluted) | -1.88 | -1.46 |
| Weighted avg. shares (diluted) | 48.30M | 46.60M |
| Balance sheet | ||
| Cash & equivalents | $95.50M | $128.57M |
| Current assets | $97.71M | $136.53M |
| PP&E, net | $20.65M | $21.00M |
| Intangibles | $193,000 | $37,000 |
| Total assets | $118.36M | $157.53M |
| Current liabilities | $43.83M | $11.75M |
| Total liabilities | $43.95M | $11.83M |
| Shareholders' equity | $74.40M | $145.70M |
| Shares outstanding | 48.31M | 48.20M |
| Cash flow statement | ||
| Operating cash flow | -$32.25M | -$116.93M |
| Capital expenditure | $581,000 | $103,000 |
| Free cash flow | -$32.83M | -$117.03M |
| Investing cash flow | -$581,000 | -$103,000 |
| Financing cash flow | -$239,000 | $124.47M |
| Depreciation & amortization | $903,000 | $952,000 |
| Stock-based compensation | $19.58M | $16.29M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.